Toxicity results after treatment with Electronic Brachytherapy in patients with endometrial cancer

Mendez Villamon, A. ; Miranda Burgos, A. ; Gascon Ferrer, M. ; Puertas Valino, M. ; Cordero, S.L. ; Martinez, A.G. ; Quintana, I.N. ; Muñoz Saenz, E. ; Riazuelo Fantova, G.R. ; Escartín Martinez, I. ; Gomez, J.F. ; Ibañez Carreras, R. (Universidad de Zaragoza) ; Tejedor Gutierrez, M.

Resumen: Poster Session [EP-2226]
Purpose or Objective To analyse the toxicity outcomes after treatment with Electronic Brachytherapy (XB) in postsurgical endometrial cancer patients treated at our medical centre. Material and Methods Prospective study in which we selected 94 patients, between September/2015 and September/2017, that received treatment with XB administered twice a week after endometrial cancer surgery, with IMRT planificati on. The patients were divided in two groups: Group 1 (57/94) considered high risk received external beam radiotherapy (46Gy) followed by XB (15Gy in 5Gy fractions) and group 2 (37/94) considered intermediate risk received exclusive XB (25Gy in 5Gy fraction s). We analysed the median dose in bladder, rectum and sigmoid D2cc, V50, V35 with XB comparing the doses with Ir192. The vaginal mucosa, gastrointestinal (GI) and genitourinary (GU) toxicities were analysed with the Common Terminology Criteria for Adverse Events (CTCAE 4.0) scale. Results The median dose in bladder with XB vs. Ir192 was: 2cc 62.9 vs. 69.9%, V50 7.1 vs. 12.6Gy, V35 15 vs. 28.1. In rectum XB vs. Ir192 was: D 2cc 64.01% vs. 67.7%, V50 7.8 vs. 10.9Gy, V35 16.5 vs. 31.8Gy. In sigmoid XB vs. Ir 192 was: D 50.37%vs. 58.0%, V50 8.8 vs. 16.2Gy, V35 21.2 vs. 37.5Gy. The median follow- up was 11 months (range 1 - 23, 9 months). In group 1, acute vaginal mucositis (G1) was observed in 35.08% of the patients, GI toxicity (G1) in 5.26% and GU toxicity (G1) in 10.52%. In group 2, we observed acute vaginal mucositis G1 in 45% of the patients and G2 in 10.81%, GI toxicity (G1) occurred in 2.7% and GU toxicity (G1) was present in 16.21%. There was no grade 3 or greater toxicity in any of the groups. Late toxici ty was observed in only 4 patients: Mucositis (G1) in 3 patients and GU toxicity (G1) in 1 patient. Conclusion The dose received by the organs at risk with the XB is less compared to Ir192, with a good coverage of the PTV. The greater toxicity was observe d immediately after the treatment was finished with an important reduction of the symptoms after 6 months. This technique shows excellent results as for toxicity.

Idioma: Inglés

DOI: 10.1016/S0167-8140(18)32535-0

Año: 2018

Publicado en: RADIOTHERAPY AND ONCOLOGY 127, Suppl. 1 (2018), S1230-S1231
ISSN: 0167-8140

Factor impacto JCR: 5.252 (2018)

Categ. JCR: RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING rank: 14 / 129 = 0.109 (2018) - Q1 - T1
Categ. JCR: ONCOLOGY rank: 46 / 229 = 0.201 (2018) - Q1 - T1

Factor impacto SCIMAGO: 2.023 - Hematology (Q1) - Radiology, Nuclear Medicine and Imaging (Q1) - Oncology (Q1)

Tipo y forma: Comunicación congreso (Versión definitiva)

Área (Departamento): Área Radiol. y Medicina Física (Dpto. Pediatría Radiol.Med.Fís)